Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | F13A1 | P00488 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | TGM1 | P22735 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30993374 | 1.00 | HTR2C (0.62) | HTR2CSMN1; SMN2NPC1RAB9ACHRNA4 | |
| SCHEMBL31288321 | 1.00 | HTR2C (0.62) | HTR2CSMN1; SMN2NPC1RAB9ACHRNA4 | |
| Hydrochloric Acid SCHEMBL19742033 | 0.99 | HTR2C (0.60) | HTR2CSMN1; SMN2NPC1RAB9ACHRNA4 | |
| SCHEMBL10054008 | 0.91 | SMN1; SMN2 (0.60) | HTR2CSMN1; SMN2NPC1RAB9ACHRNA4 | |
| SCHEMBL7195745 | 0.89 | HTR2C (0.54) | HTR2CSMN1; SMN2NPC1RAB9ACHRNA4 | |
| SCHEMBL3717717 | 0.86 | SMN1; SMN2 (0.64) | HTR2CSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL12836007 | 0.86 | SMN1; SMN2 (0.60) | HTR2CSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL3628114 | 0.86 | SMN1; SMN2 (0.60) | HTR2CSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL31229906 | 0.86 | SMN1; SMN2 (0.54) | HTR2CSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL24025419 | 0.85 | SMN1; SMN2 (0.67) | HTR2CSMN1; SMN2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174879-B1 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2018-07-18 | — | — | EP | disclosed |
| EP-3174879-B1 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2018-07-18 | — | — | EP | disclosed |
| EP-3174879-A1 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C | Boehringer Ingelheim International GmbH (DE) | 2017-06-07 | — | — | EP | disclosed |
| US-9440960-B2 | Substituted oxetanes and their use as inhibitors of cathepsin C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-09-13 | — | — | US | disclosed |
| US-9440960-B2 | Substituted oxetanes and their use as inhibitors of cathepsin C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-09-13 | — | — | US | disclosed |
| WO-2016016242-A1 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
| US-20160031861-A1 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-04 | — | — | US | disclosed |
| US-20160031861-A1 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-04 | — | — | US | disclosed |
| WO-2016016242-A1 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
| US-7144914-B2 | 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1360187-B1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
| EP-1360187-A1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002060902-A1 | 3,7-DIAZABICYCLO[3.3.0]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, CACNA1E | HTR2C 2892/4885SMN1; SMN2 3434/4885NPC1 1255/4885 |
| US-20160031861-A1 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C | CTSE, CTSC, CTSZ | HTR2C 1881/4885SMN1; SMN2 3971/4885NPC1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.